Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Akt Inhibitor
Hu7691 is a selective Akt inhibitor that exhibits potent inhibitory activity with IC50 values of 4.0 nM, 97.5 nM, and 28 nM against Akt1, Akt2, and Akt3, respectively. This compound has been shown to inhibit tumor growth while reducing cutaneous toxicity in mouse models, making it a valuable tool for cancer research. Its specificity and efficacy position Hu7691 as a promising reagent for studies focused on the Akt signaling pathway and its role in tumorigenesis. -
pan-AKT Inhibitor
Vevorisertib is a potent and selective pan-AKT serine/threonine kinase inhibitor, effectively targeting AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). This orally active compound demonstrates significant biological activity in inhibiting AKT pathways and is applicable in the study of solid tumors harboring PIK3CA, AKT, or PTEN mutations. Vevorisertib can be utilized as a monotherapy or in combination with other anti-cancer agents for enhanced therapeutic efficacy in cancer research. -
Akt Inhibitor
GSK2110183 analog 1 hydrochloride is a structural analogue designed to inhibit Akt, a critical signaling protein involved in various cellular processes such as growth, survival, and metabolism. This compound demonstrates potent Akt inhibitory activity, making it a valuable tool for studying the role of Akt in cancer progression and treatment. Its applications extend to exploring therapeutic strategies targeting the Akt pathway in various disease models. -
PI3K-Akt Inhibitor
AKT Inhibitor IV is a potent PI3K-Akt pathway inhibitor that selectively targets the E isomer. This compound exhibits significant cytotoxic effects, making it valuable for research applications focusing on cell proliferation, survival, and apoptosis. It is ideal for studies investigating the role of the PI3K-Akt signaling pathway in cancer and other diseases. -
AKT Inhibitor
CCT128930 hydrochloride is a selective inhibitor of AKT, demonstrating an IC50 of 6 nM. It exhibits significant selectivity, being 28-fold more potent against AKT than the closely related PKA kinase (IC50 of 168 nM) and 20-fold more effective than p70S6K (IC50 of 120 nM). CCT128930 hydrochloride is recognized for its ability to induce cell cycle arrest, promote DNA damage, and stimulate autophagy, enabling its application in cancer research and potential antitumor strategies. -
Allosteric Akt Inhibitor
Pifusertib is a selective, orally active allosteric inhibitor of Akt, exhibiting IC50 values of 4.8, 1.6, and 44 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anti-myeloma activity and intensifies lethal endoplasmic reticulum (ER) stress resulting from proteasome inhibition. In addition, Pifusertib promotes both apoptosis and autophagy, making it a useful tool for research in cancer biology and therapeutic development. -
Allosteric Akt Inhibitor
MK-2206 is a highly potent and selective allosteric inhibitor of the Akt signaling pathway, exhibiting IC50 values of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anticancer activity, particularly in breast cancer cell lines and those harboring PIK3CA mutations or loss of PTEN function. MK-2206 is valuable for research investigating Akt's role in cancer progression and therapeutic resistance. -
AKT1/2 Inhibitor
Engasertib is a potent and selective inhibitor of AKT1 and AKT2, displaying IC50 values of 0.13 µM and 0.09 µM, respectively, with a slightly lower potency against AKT3 at 2.75 µM. This compound effectively inhibits AKT phosphorylation, leading to modulation of downstream signaling pathways in vitro. Due to its ability to suppress cancer cell proliferation and tumor growth, Engasertib serves as a valuable tool for cancer research and therapeutic development. -
PI3K/AKT/mTOR Inhibitor
Notoginsenoside Ft1 is a potent PI3K/AKT/mTOR inhibitor with significant bioactive properties. This compound induces apoptosis and lysosomal cell death in various cancer cell types by modulating key signaling pathways, such as p38 MAPK and ERK1/2, while promoting angiogenesis. Additionally, Notoginsenoside Ft1 enhances CD8+ T cell populations and exerts vasodilatory effects through glucocorticoid and estrogen receptor beta activation in endothelial cells. By acting as a TGR5 agonist and FXR antagonist, it may provide protective effects against renal injury and contribute to the management of obesity and insulin resistance through the modulation of intracellular calcium and cAMP levels. -
pan-AKT/AKT1-E17K Mutant Inhibitor
Vevorisertib trihydrochloride is a selective, allosteric inhibitor targeting pan-AKT and the AKT1-E17K mutant. It effectively inhibits AKT phosphorylation, demonstrating Kd values of 1.2 nM for AKT1 and 8.6 nM for AKT1-E17K, along with IC50 values of 0.55 nM, 0.81 nM, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. This compound is valuable for cancer research, aiding in the exploration of therapeutic strategies targeting the AKT signaling pathway. -
Allosteric Akt Inhibitor
Pifusertib hydrochloride is a selective allosteric inhibitor of Akt, exhibiting IC50 values of 4.8 nM, 1.6 nM, and 44 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anti-myeloma activity by enhancing endoplasmic reticulum stress in the context of proteasome inhibition. Additionally, Pifusertib hydrochloride induces both apoptosis and autophagy, making it a valuable tool for research into cancer therapies and the modulation of cellular stress responses. -
AKT/mTOR Inhibitor
19-epi-Scholaricine is a potent AKT/mTOR inhibitor, classified as an orally active indole alkaloid. This compound downregulates profibrotic and apoptotic proteins, such as HRAS, HSP90AA1, and KDR, while upregulating the cell cycle regulator CDK2. Furthermore, 19-epi-Scholaricine inhibits ROS production and reduces inflammatory mediator release, leading to decreased podocyte apoptosis, renal inflammation, and oxidative stress. It is a valuable tool for research into chronic glomerulonephritis and membranous nephropathy. -
PI3K/Akt Inhibitor, MAPK Inhibitor, NF-κB Inhibitor, Nrf2/ARE Activator
JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms. -
Akt/ROCK Inhibitor
Akt/ROCK-IN-1 is a potent dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively. This compound demonstrates significant antitumor activity, particularly in neuroblastoma models. It serves as a valuable tool for research into cancer biology and therapeutic development. -
AKT inhibitor
TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. -
AKT inhibitor
Afuresertib, also known as GSK2110183, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. It binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. -
AKT Inhibitor
Triciribine, also known as API-2, suppresses the phosphorylation level and kinase activity of Akt. -
Akt inhibitor
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Aktwt. -
Akt Inhibitor
GDC-0068 is a selective, ATP-competitive, pan-Akt inhibitor that targets Akt1, 2, and 3 with IC50 values of 5, 18, and 8 nM, respectively in cell-free assays -
multi-kinase inhibitor
Cenisertib (AS-703569) is a multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. -
Akt kinase inhibitor
AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity. -
Akt inhibitor
Isobavachalcone (Corylifolinin) is derived from Psoralea corylifolia Linn. and is a potent inhibitor of Akt signaling pathway, which induces apoptosis in human cancer cells (Inhibits OVCAR-8 cell growth with an IC50 value of 7.92 μM). -
AKT/PKB inhibitor
10-DEBC HCl is a selective inhibitor of Akt/PKB. It inhibits IGF-1-stimulated phosphorylation and activation of Akt (complete inhibition at 2.5 μM), suppressing downstream activation of mTOR, p70 S6 kinase and S6 ribosomal protein. -
Broad-Spectrum Kinase Inhibitor
CTX-0294885 is a novel broad-spectrum kinase inhibitor. CTx-0294885 exhibits inhibitory activity against a broad range of kinases in vitro. -
PI3K/Akt inhibitor
Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa -
Akt inhibitor
Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. -
ERK/Akt/NF-kB inhibitor
Tomatidine inhibits the phosphorylation of ERK, Akt, and the nuclear content of NF-kB. possess anti-inflammatory properties. -
AKT 1/2 inhibitor
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity. -
AKT inhibitor
ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3). -
Akt inhibitor
Afuresertib is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. -
pan-Akt inhibitor
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5/18/8 nM, 620-fold selectivity over PKA. -
NF-κB inhibitor
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B is also a regulator of skeletal muscle mass. -
Akt inhibitor
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. -
ATP-competitive AKT inhibitor
Solenopsin is an ATP-competitive AKT inhibitor with IC50 value of 10 μM . -
allosteric Akt1/Akt2 inhibitor
BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively. -
Akt inhibitor
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively, little activity outside the AGC kinase family. -
PI3k/Akt/mTOR Inhibitor
D-87503 is a potent inhibitor of the PI3K/Akt/mTOR signaling pathway, exhibiting IC50 values of 62 nM for PI3K and 0.76 μM for Erk2. This compound effectively attenuates the activity of downstream substrates, including Akt and Rsk1, making it a valuable tool for studying cellular processes regulated by this pathway. D-87503 has applications in cancer research and investigates the role of PI3K signaling in various physiological conditions.
